Laboratory of Clinical Neurophysiology, School of Medicine, University of São Paulo, and Hospital das Clínicas, São Paulo, Brazil.
Pediatr Neurol. 2012 Jul;47(1):47-50. doi: 10.1016/j.pediatrneurol.2012.04.026.
Individuals treated with combined valproate-lamotrigine rarely present late adverse effects (unrelated to introduction and titration). We describe four patients in whom such effects occurred after continuous, long-term use of valproate-lamotrigine (at 9 months to 2 years after final antiepileptic drug adjustment). The patients presented heterogeneous disturbances, including ataxia, vertigo, and headache, and rare movement disorders, such as tics and abnormal eye movements. Although these effects are heterogeneous in their occurrence and timing, they can alert physicians to the possibility of late neurologic disturbances, and must be considered in order to avoid unnecessary ancillary tests. Treatment discontinuation is unnecessary, given that a small decrease in dose led to remission of these adverse effects.
联合使用丙戊酸钠-拉莫三嗪治疗的患者很少出现迟发性不良反应(与起始和滴定无关)。我们描述了 4 例患者,他们在丙戊酸钠-拉莫三嗪连续长期使用(最后一次调整抗癫痫药物后 9 个月至 2 年)后出现了这些不良反应。这些患者表现出不同的紊乱,包括共济失调、眩晕和头痛,以及罕见的运动障碍,如抽搐和异常眼球运动。尽管这些不良反应的发生和时间存在异质性,但它们可以提醒医生注意迟发性神经紊乱的可能性,必须加以考虑,以避免不必要的辅助检查。停止治疗是不必要的,因为小剂量减少导致这些不良反应缓解。